Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| TriSalus Life Sciences, Inc. | 1,065,215 | reported | 15 May 2026 | tx 22+1,756,804−20,302 |
| Absci Corp | 178,400 | reported | 07 Jul 2025 | tx 1+178,400 |
| ABBOTT LABORATORIES | 148,998 | reported | 14 Dec 2011 | tx 132+533,375−329,167 |
| Kura Oncology, Inc. | 28,500 | reported | 05 Jun 2025 | tx 9+200,083 |
| Omega Therapeutics, Inc. |
Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 9 buys in history.
| 25,000 |
| reported |
| 20 Jun 2024 |
| tx 3+61,236 |
| QLT INC/BC | 6,632 | reported | 09 May 2017 | tx 5+429,635−8,880 |
| ALIMERA SCIENCES INC | 3,333 | reported | 18 Jun 2020 | tx 3+93,333 |
| Coherus Oncology, Inc. | 0 | reported | 22 Jun 2020 | tx 14+184,997−109,994 |
| Aegerion Pharmaceuticals, Inc. | 0 | reported | 29 Nov 2016 | tx 6+891,000−891,000 |
| Prometheus Biosciences, Inc. | 0 | reported | 16 Jun 2023 | tx 6+62,571−62,571 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 15 May 2026 | PURCHASE | TriSalus Life Sciences, Inc. | 39,682 | 2.59 USD | anomaly |
| 17 Mar 2026 | SALE | TriSalus Life Sciences, Inc. | 15,944 | 3.85 USD | |
| 11 Mar 2026 | SALE | TriSalus Life Sciences, Inc. | 4,358 | 4.13 USD | |
| 23 Feb 2026 | PURCHASE | TriSalus Life Sciences, Inc. | 30,487 | 4.10 USD | first after silenceanomaly |
| 24 Nov 2025 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 300,000 | 0.00 USD | |
| 24 Nov 2025 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 125,000 | 0.00 USD | |
| 13 Feb 2024 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 125,000 | 0.00 USD | |
| 24 Nov 2025 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 250,000 | 0.00 USD | deriv |
| 07 Jul 2025 | GRANT_AWARD | Absci Corp | 178,400 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | Kura Oncology, Inc. | 28,500 | 0.00 USD | deriv |
| 18 Feb 2025 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 21,089 | 0.00 USD | |
| 30 Jan 2025 | PURCHASE | TriSalus Life Sciences, Inc. | 5,010 | 5.28 USD | |
| 29 Jan 2025 | PURCHASE | TriSalus Life Sciences, Inc. | 5,030 | 5.03 USD | |
| 28 Jan 2025 | PURCHASE | TriSalus Life Sciences, Inc. | 4,716 | 5.12 USD | |
| 27 Jan 2025 | PURCHASE | TriSalus Life Sciences, Inc. | 4,826 | 5.42 USD | |
| 27 Jan 2025 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 40,000 | 0.00 USD | |
| 27 Jan 2025 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 240,000 | 0.00 USD | deriv |
| 13 Sept 2024 | PURCHASE | TriSalus Life Sciences, Inc. | 1,295 | 4.83 USD | anomaly |
| 12 Sept 2024 | PURCHASE | TriSalus Life Sciences, Inc. | 7,520 | 5.20 USD | |
| 13 Sept 2024 | PURCHASE | TriSalus Life Sciences, Inc. | 6,000 | 5.00 USD | |
| 10 Sept 2024 | PURCHASE | TriSalus Life Sciences, Inc. | 5,000 | 4.97 USD | |
| 20 Jun 2024 | GRANT_AWARD | Omega Therapeutics, Inc. | 25,000 | 0.00 USD | deriv |
| 05 Jun 2024 | GRANT_AWARD | Kura Oncology, Inc. | 26,000 | 0.00 USD | deriv |
| 13 Feb 2024 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 84,899 | 0.00 USD | |
| 13 Feb 2024 | GRANT_AWARD | TriSalus Life Sciences, Inc. | 288,750 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 23 Feb 2026.